|TARGIT Therapy for Breast Cancer|
The TARGIT Trial
|TARGIT Definitive Treatment|
The TARGIT trial is an international randomized clinical trial designed to test the hypothesis that the strategy of delivering a single dose of targeted intraoperative radiotherapy in women with early breast cancer is equivalent to a conventional course of post-operative external beam radiotherapy (EBRT). The primary endpoints are local and loco-regional recurrence rates.
Breast-Conserving Radiotherapy, when conventional external beam radiation therapy (EBRT) is not an option
In patients presenting with a local recurrence after previous radiotherapy, repeated external irradiation is no longer indicated in many cases, leaving radical mastectomy as the only treatment alternative. Radiotherapy with INTRABEAM can provide a treatment option for patients after external irradiation is no longer indicated, offering an important alternative improving quality of life and treatment outcomes.
|Kraus-Tiefenbacher et al.: Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy. BMC Cancer 2007; 7:178.|
Keshtgar et al.: Use of intra-operative radiotherapy [IORT] alone in breast cancer patients when conventional external beam radiation therapy [EBRT] was not possible. Proceedings ESSO, 2006
|More information on the TARGIT trial|